CALL FOR PAPERS

Interferon (IFN) is the largest cytokine family. IFN is subdivided into 3 types that share a common antiviral characteristic. Type I IFN, commonly represented by IFN-/, was introduced to the clinic as a treatment for infectious diseases, multiple sclerosis, and cancer. Type II IFN consists of IFN- which is not commonly used in clinic. Type III IFN, also called IFN-, is the newly discovered IFN. Although IFN- showed significant benefits to patients with hepatitis C virus infection in clinical trials, its clinical use is still not yet effective.

In spite of being powerful modulators in immunity, infections, and neoplasms, IFNs are usually considered with lesser enthusiasm at the expense of emerging therapies. Our objective in this special issue is to deeply appraise the challenges of IFN therapy and also project new clinical perspectives.

We invite authors to contribute original research articles as well as review articles on interferon and therapy. We especially welcome original research articles related to the role of IFN in cancer, infection, inflammation, and immunotherapy.

Potential topics include but are not limited to the following:

- ▶ Benefits of IFNs as natural antiviral and immunomodulatory agents

- ▶ Landscape of IFN therapy in the clinic

- ▶ IFN therapy: mechanisms of action and side effects

- ▶ Fitting the IFN pathways in current cancer immunotherapies

- ▶ IFN- and current advances in multiple sclerosis

- ▶ Clinical perspectives of IFN- in cancer and infection diseases

- ▶ Distinct roles of IFN- and IFN- in viral infections

Authors can submit their manuscripts through the Manuscript Tracking System at https://mts.hindawi.com/submit/journals/jir/pcit/.

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor
Ahmed Lasfar, Rutgers University, Piscataway, USA
ahmed.lasfar@pharmacy.rutgers.edu

Guest Editors
Andrew Zloza, Rutgers University, New Brunswick, USA
andrew_zloza@rush.edu

Antonio Rivero, Cordova University, Córdoba, Spain
ariveror@gmail.com